Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Scheduled to Post Earnings on Monday
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is scheduled to issue its quarterly earnings data on Monday, August 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%. On average, analysts expect Corbus Pharmaceuticals Holdings to post $-0.74 EPS for the current fiscal year and $-0.66 EPS for the next fiscal year.
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) opened at 6.00 on Monday. The firm’s 50-day moving average price is $6.26 and its 200 day moving average price is $7.15. The firm’s market cap is $301.31 million. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $2.80 and a one year high of $10.78.
Several equities research analysts have weighed in on the company. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Saturday, May 6th. BidaskClub cut Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Cantor Fitzgerald set a $24.00 target price on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $20.50.
TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-scheduled-to-post-earnings-on-monday.html.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.